|
|
cetuximab A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonyms: | | Anti-EGFR Monoclonal Antibody Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 monoclonal antibody Chimeric Anti-EGFR Monoclonal Antibody Chimeric Monoclonal Antibody C225 Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 gamma1-chain), disulfide with human-mouse monoclonal C225 kappa-chain, dimer monoclonal antibody C225 | | | US brand name: | | Erbitux | | | Abbreviations: | | Chimeric MoAb C225 MOAB C225 | | | Code names: | | C225 IMC-C225 | | |
|
|